Showing results (261-270 of 406) with videos related to
Sort By:
Pageof 41
Nuclear Medicine and Biology|September 3, 1999
PET examination of three potent cocaine derivatives as specific radioligands for the serotonin transporterJ Helfenbein, J Sandell, C Halldin, et al.The Journal of Comparative Neurology|July 15, 1999
Preprotachykinin-A mRNA expression in the human and monkey brain: An in situ hybridization studyY L Hurd, E Keller, P Sotonyi, et al.Psychiatry Research|May 1, 1980
Changes in endorphins and 5-hydroxyindoleacetic acid in cerebrospinal fluid as a result of treatment with a serotonin reuptake inhibitor (zimelidine) in chronic pain patientsF Johansson, L von Knorring, G Sedvall, et al.The European Journal of Neuroscience|June 1, 1997
Localization of neuropeptide Y Y1 mRNA in the human brain: abundant expression in cerebral cortex and striatumL Caberlotto, K Fuxe, G Sedvall, et al.The American Journal of Physiology|May 1, 1990
Cerebral blood flow and substrate utilization in insulin-treated diabetic subjectsV Grill, M Gutniak, O Björkman, et al.Acta Psychiatrica Scandinavica|August 1, 1977
Effect of chlorpromazine treatment on monoamine metabolite levels in cerebrospinal fluid of psychotic patientsB Wode-Helgodt, B Fyrö, B Gullberg, et al.Psychopharmacology|March 23, 1977
Mass fragmentographic analysis of clomipramine and its mono-demethylated metabolite in human plasmaG Alfredsson, F A Wiesel, B Fyro, et al.Psychopharmacology|August 8, 1979
Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatmentC Härnryd, L Bjerkenstedt, V E Grimm, et al.The American Journal of Clinical Nutrition|November 1, 1982
High level of pyridoxal 5'-phosphate in the cerebrospinal fluid of adult celiac patientsC Hallert, S Allenmark, U Larsson-Cohn, et al.Acta Psychiatrica Scandinavica|August 1, 1978
Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazineB Wode-Helgodt, S Borg, B Fyrö, et al.Pageof 41